Online inquiry

IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5081MR)

This product GTTS-WQ5081MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2RA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001161529.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1438
UniProt ID P15509
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5081MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1585MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ12970MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ13838MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ6144MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ11056MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ11723MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ9661MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ15897MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XMT-1536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW